These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

113 related articles for article (PubMed ID: 27043998)

  • 1. Second generation of thiazolylmannosides, FimH antagonists for E. coli-induced Crohn's disease.
    Chalopin T; Alvarez Dorta D; Sivignon A; Caudan M; Dumych TI; Bilyy RO; Deniaud D; Barnich N; Bouckaert J; Gouin SG
    Org Biomol Chem; 2016 Apr; 14(16):3913-25. PubMed ID: 27043998
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The Antiadhesive Strategy in Crohn's Disease: Orally Active Mannosides to Decolonize Pathogenic Escherichia coli from the Gut.
    Alvarez Dorta D; Sivignon A; Chalopin T; Dumych TI; Roos G; Bilyy RO; Deniaud D; Krammer EM; de Ruyck J; Lensink MF; Bouckaert J; Barnich N; Gouin SG
    Chembiochem; 2016 May; 17(10):936-52. PubMed ID: 26946458
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Development of Heptylmannoside-Based Glycoconjugate Antiadhesive Compounds against Adherent-Invasive Escherichia coli Bacteria Associated with Crohn's Disease.
    Sivignon A; Yan X; Alvarez Dorta D; Bonnet R; Bouckaert J; Fleury E; Bernard J; Gouin SG; Darfeuille-Michaud A; Barnich N
    mBio; 2015 Nov; 6(6):e01298-15. PubMed ID: 26578673
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Thiazolylaminomannosides as potent antiadhesives of type 1 piliated Escherichia coli isolated from Crohn's disease patients.
    Brument S; Sivignon A; Dumych TI; Moreau N; Roos G; Guérardel Y; Chalopin T; Deniaud D; Bilyy RO; Darfeuille-Michaud A; Bouckaert J; Gouin SG
    J Med Chem; 2013 Jul; 56(13):5395-406. PubMed ID: 23795713
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Physiochemical Tuning of Potent Escherichia coli Anti-Adhesives by Microencapsulation and Methylene Homologation.
    Alvarez Dorta D; Chalopin T; Sivignon A; de Ruyck J; Dumych TI; Bilyy RO; Deniaud D; Barnich N; Bouckaert J; Gouin SG
    ChemMedChem; 2017 Jun; 12(12):986-998. PubMed ID: 28257558
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Rational design strategies for FimH antagonists: new drugs on the horizon for urinary tract infection and Crohn's disease.
    Mydock-McGrane LK; Hannan TJ; Janetka JW
    Expert Opin Drug Discov; 2017 Jul; 12(7):711-731. PubMed ID: 28506090
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The potential of FimH as a novel therapeutic target for the treatment of Crohn's disease.
    Sivignon A; Bouckaert J; Bernard J; Gouin SG; Barnich N
    Expert Opin Ther Targets; 2017 Sep; 21(9):837-847. PubMed ID: 28762293
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Mannose-derived FimH antagonists: a promising anti-virulence therapeutic strategy for urinary tract infections and Crohn's disease.
    Mydock-McGrane LK; Cusumano ZT; Janetka JW
    Expert Opin Ther Pat; 2016; 26(2):175-97. PubMed ID: 26651364
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Sites for Dynamic Protein-Carbohydrate Interactions of O- and C-Linked Mannosides on the E. coli FimH Adhesin.
    Touaibia M; Krammer EM; Shiao TC; Yamakawa N; Wang Q; Glinschert A; Papadopoulos A; Mousavifar L; Maes E; Oscarson S; Vergoten G; Lensink MF; Roy R; Bouckaert J
    Molecules; 2017 Jul; 22(7):. PubMed ID: 28671638
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Development of Mannopyranoside Therapeutics against Adherent-Invasive Escherichia coli Infections.
    Mousavifar L; Touaibia M; Roy R
    Acc Chem Res; 2018 Nov; 51(11):2937-2948. PubMed ID: 30289687
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Inhibition profiles of mono- and polyvalent FimH antagonists against 10 different Escherichia coli strains.
    Chalopin T; Brissonnet Y; Sivignon A; Deniaud D; Cremet L; Barnich N; Bouckaert J; Gouin SG
    Org Biomol Chem; 2015 Dec; 13(46):11369-75. PubMed ID: 26440382
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Heptyl α-D-mannosides grafted on a β-cyclodextrin core to interfere with Escherichia coli adhesion: an in vivo multivalent effect.
    Bouckaert J; Li Z; Xavier C; Almant M; Caveliers V; Lahoutte T; Weeks SD; Kovensky J; Gouin SG
    Chemistry; 2013 Jun; 19(24):7847-55. PubMed ID: 23595913
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Antivirulence Isoquinolone Mannosides: Optimization of the Biaryl Aglycone for FimH Lectin Binding Affinity and Efficacy in the Treatment of Chronic UTI.
    Jarvis C; Han Z; Kalas V; Klein R; Pinkner JS; Ford B; Binkley J; Cusumano CK; Cusumano Z; Mydock-McGrane L; Hultgren SJ; Janetka JW
    ChemMedChem; 2016 Feb; 11(4):367-73. PubMed ID: 26812660
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Design, synthesis and biological evaluation of mannosyl triazoles as FimH antagonists.
    Schwardt O; Rabbani S; Hartmann M; Abgottspon D; Wittwer M; Kleeb S; Zalewski A; Smieško M; Cutting B; Ernst B
    Bioorg Med Chem; 2011 Nov; 19(21):6454-73. PubMed ID: 21962988
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Improvement of Aglycone π-Stacking Yields Nanomolar to Sub-nanomolar FimH Antagonists.
    Schönemann W; Cramer J; Mühlethaler T; Fiege B; Silbermann M; Rabbani S; Dätwyler P; Zihlmann P; Jakob RP; Sager CP; Smieško M; Schwardt O; Maier T; Ernst B
    ChemMedChem; 2019 Apr; 14(7):749-757. PubMed ID: 30710416
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Receptor binding studies disclose a novel class of high-affinity inhibitors of the Escherichia coli FimH adhesin.
    Ratliff TL
    J Urol; 2005 Sep; 174(3):1150. PubMed ID: 16094085
    [No Abstract]   [Full Text] [Related]  

  • 17. FimH antagonists: bioisosteres to improve the in vitro and in vivo PK/PD profile.
    Kleeb S; Pang L; Mayer K; Eris D; Sigl A; Preston RC; Zihlmann P; Sharpe T; Jakob RP; Abgottspon D; Hutter AS; Scharenberg M; Jiang X; Navarra G; Rabbani S; Smiesko M; Lüdin N; Bezençon J; Schwardt O; Maier T; Ernst B
    J Med Chem; 2015 Mar; 58(5):2221-39. PubMed ID: 25666045
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Receptor binding studies disclose a novel class of high-affinity inhibitors of the Escherichia coli FimH adhesin.
    Bouckaert J; Berglund J; Schembri M; De Genst E; Cools L; Wuhrer M; Hung CS; Pinkner J; Slättegård R; Zavialov A; Choudhury D; Langermann S; Hultgren SJ; Wyns L; Klemm P; Oscarson S; Knight SD; De Greve H
    Mol Microbiol; 2005 Jan; 55(2):441-55. PubMed ID: 15659162
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Structure-based drug design and optimization of mannoside bacterial FimH antagonists.
    Han Z; Pinkner JS; Ford B; Obermann R; Nolan W; Wildman SA; Hobbs D; Ellenberger T; Cusumano CK; Hultgren SJ; Janetka JW
    J Med Chem; 2010 Jun; 53(12):4779-92. PubMed ID: 20507142
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Lead optimization studies on FimH antagonists: discovery of potent and orally bioavailable ortho-substituted biphenyl mannosides.
    Han Z; Pinkner JS; Ford B; Chorell E; Crowley JM; Cusumano CK; Campbell S; Henderson JP; Hultgren SJ; Janetka JW
    J Med Chem; 2012 Apr; 55(8):3945-59. PubMed ID: 22449031
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.